J. Avila Marrero

J. Avila Marrero's AcademicInfluence.com Rankings

J. Avila Marrero

Philosophy

#8009

World Rank

#11307

Historical Rank

Logic

#5045

World Rank

#6403

Historical Rank

philosophy Degrees

Download Badge

Philosophy

J. Avila Marrero's Degrees

PhD Biomedical Sciences University of California, San Francisco
Doctorate Medicine Stanford University

Why Is J. Avila Marrero Influential?

(Suggest an Edit or Addition)

(See a Problem?)

J. Avila Marrero's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C (2003) (3688)
AASLD guidelines for the treatment of hepatocellular carcinoma (2018) (2569)
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases (2018) (2291)
NCCN clinical practice guidelines in oncology: hepatobiliary cancers. (2009) (2154)
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases (2019) (1451)
Diagnosis and treatment of hepatocellular carcinoma. (2008) (1322)
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. (2012) (707)
NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. (2002) (622)
Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort (2005) (614)
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. (2009) (576)
Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. (2018) (542)
Circulating MicroRNAs in Patients with Chronic Hepatitis C and Non-Alcoholic Fatty Liver Disease (2011) (510)
Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. (2005) (460)
Des‐gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients (2003) (383)
MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. (2008) (367)
Virologic response and resistance to adefovir in patients with chronic hepatitis B. (2006) (341)
GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. (2005) (339)
ACG Clinical Guideline: The Diagnosis and Management of Focal Liver Lesions (2014) (305)
Comparison of imputation methods for missing laboratory data in medicine (2013) (284)
Identification of osteopontin as a novel marker for early hepatocellular carcinoma (2012) (273)
The Effect of PNPLA3 on Fibrosis Progression and Development of Hepatocellular Carcinoma: A Meta-analysis (2014) (259)
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. (2016) (246)
Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially‐enhancing liver mass (2005) (228)
Portal vein thrombosis and survival in patients with cirrhosis (2010) (221)
Effectiveness of Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis (2012) (214)
Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis (2017) (212)
Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. (2005) (210)
Detection of Hepatocellular Carcinoma at Advanced Stages Among Patients in the HALT-C Trial: Where Did Surveillance Fail? (2013) (189)
Newer markers for hepatocellular carcinoma. (2004) (186)
Machine Learning Algorithms Outperform Conventional Regression Models in Predicting Development of Hepatocellular Carcinoma (2013) (172)
Failure Rates in the Hepatocellular Carcinoma Surveillance Process (2012) (168)
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference (2020) (164)
Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: A safe and effective bridge to liver transplantation (2002) (158)
Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. (2005) (155)
Establishment of a Multidisciplinary Hepatocellular Carcinoma Clinic is Associated with Improved Clinical Outcome (2013) (155)
An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis (2017) (154)
Renal outcomes after liver transplantation in the model for end‐stage liver disease era (2009) (146)
Novel Fucosylated Biomarkers for the Early Detection of Hepatocellular Carcinoma (2009) (144)
An intention‐to‐treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data (2009) (143)
Emerging Trends in Hepatocellular Carcinoma: Focus on Diagnosis and Therapeutics (2014) (142)
Burden of cirrhosis on older Americans and their families: Analysis of the health and retirement study (2012) (142)
Two-color, rolling-circle amplification on antibody microarrays for sensitive, multiplexed serum-protein measurements (2004) (141)
Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. (2007) (141)
Modified Charlson Comorbidity Index for predicting survival after liver transplantation (2007) (140)
Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice (2011) (136)
SELDI‐TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma (2005) (133)
The challenge of prognosis and staging for hepatocellular carcinoma. (2010) (130)
Lack of tumor seeding of hepatocellular carcinoma after percutaneous needle biopsy using coaxial cutting needle technique. (2006) (124)
Patient‐reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis (2016) (124)
Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liver (2010) (112)
Recent advances in the treatment of hepatocellular carcinoma (2010) (110)
First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non‐interventional study (2012) (110)
Racial and Ethnic Differences in Presentation and Outcomes of Hepatocellular Carcinoma (2019) (109)
TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. (2016) (105)
Increased Levels of Galactose-Deficient Anti-Gal Immunoglobulin G in the Sera of Hepatitis C Virus-Infected Individuals with Fibrosis and Cirrhosis (2007) (105)
Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence (2007) (98)
GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score (2018) (97)
Pathogenic Escherichia coli increase Cl- secretion from intestinal epithelia by upregulating galanin-1 receptor expression. (1999) (95)
Hepatocellular Carcinoma Screening Associated with Early Tumor Detection and Improved Survival Among Patients with Cirrhosis in the US. (2017) (91)
Screening tests for hepatocellular carcinoma. (2005) (90)
Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta‐Analysis (2020) (90)
Dextran sulfate sodium-induced murine colitis activates NF-kappaB and increases galanin-1 receptor expression. (2000) (90)
Patient Involvement in Healthcare is Associated With Higher Rates of Surveillance for Hepatocellular Carcinoma (2011) (82)
Azoxymethane-induced fulminant hepatic failure in C57BL/6J mice: characterization of a new animal model. (1999) (74)
Cleavage of endoplasmic reticulum proteins in hepatocellular carcinoma: Detection of generated fragments in patient sera. (2006) (73)
Identification and confirmation of biomarkers using an integrated platform for quantitative analysis of glycoproteins and their glycosylations. (2010) (71)
Review article: new therapeutic interventions for advanced hepatocellular carcinoma (2019) (71)
Mailed Outreach Program Increases Ultrasound Screening of Patients With Cirrhosis for Hepatocellular Carcinoma. (2017) (70)
Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis (2020) (70)
Galanin-1 receptor up-regulation mediates the excess colonic fluid production caused by infection with enteric pathogens (2000) (69)
NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States (2002) (68)
Alpha-fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the American Association for the Study of Liver Diseases. (2011) (63)
Therapeutic delays lead to worse survival among patients with hepatocellular carcinoma. (2013) (62)
Current approaches to the treatment of early hepatocellular carcinoma. (2010) (53)
International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. (2021) (51)
Incidence and Risk Factors of Hepatocellular Carcinoma Recurrence After Liver Transplantation in the MELD Era (2012) (51)
Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis (2020) (48)
Advances in critical care hepatology. (2003) (48)
Modern diagnosis and management of hepatocellular carcinoma. (2009) (48)
Geographic Variation in Organ Availability Is Responsible for Disparities in Liver Transplantation between Hispanics and Caucasians (2009) (47)
Recent advances in the treatment of hepatocellular carcinoma (2013) (46)
Final analysis of GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma [HCC] and of Its Treatment with Sorafenib [Sor]) in >3000 Sor-treated patients (pts): Clinical findings in pts with liver dysfunction. (2013) (46)
Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit? (2004) (45)
Biomarkers for the Early Detection of Hepatocellular Carcinoma (2020) (45)
HCC Surveillance Improves Early Detection, Curative Treatment Receipt, and Survival in Patients with Cirrhosis: A Systematic Review and Meta-Analysis. (2022) (45)
Regional differences in sorafenib‐treated patients with hepatocellular carcinoma: GIDEON observational study (2016) (45)
Endoscopic transpapillary drainage of pancreatic abscess: technique and results. (2000) (44)
The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: notes from a recent workshop. (2008) (43)
Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase (2017) (43)
Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. (2012) (42)
Multidisciplinary Management of Hepatocellular Carcinoma: Where Are We Today? (2013) (42)
Human colonic epithelial cells express galanin-1 receptors, which when activated cause Cl- secretion. (1999) (41)
Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) second interim analysis in more than 1,500 patients: Clinical findings in patients with liver dysfunction. (2011) (41)
The Doylestown Algorithm: A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma (2015) (41)
Changes in the Glycosylation of Kininogen and the Development of a Kininogen-Based Algorithm for the Early Detection of HCC (2017) (38)
Hepatocellular carcinoma. (2005) (36)
Novel Changes in Glycosylation of Serum Apo-J in Patients with Hepatocellular Carcinoma (2011) (35)
Bacteremic pneumococcal infections in immunocompromised patients without AIDS: the impact of beta-lactam resistance on mortality. (2003) (35)
Azoxymethane-induced fulminant hepatic failure in C57BL/6J mice: characterization of a new animal model. (1999) (32)
Hospital Volume and Survival After Hepatocellular Carcinoma Diagnosis (2016) (32)
Screening process failures for hepatocellular carcinoma. (2014) (31)
Vascular Invasion and Metastasis is Predictive of Outcome in Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. (2017) (31)
Viral hepatitis and hepatocellular carcinoma. (2007) (31)
Early detection of liver cancer: Diagnosis and management (2008) (30)
Effect of hospital safety net designation on treatment use and survival in hepatocellular carcinoma (2018) (30)
Total serum glycan analysis is superior to lectin‐FLISA for the early detection of hepatocellular carcinoma (2013) (29)
Knowledge of Hepatocellular Carcinoma Screening Guidelines and Clinical Practices Among Gastroenterologists (2011) (29)
The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre (2010) (28)
A multidisciplinary approach to the management of hepatocellular carcinoma. (2010) (28)
Dynamic Changes in Ultrasound Quality for Hepatocellular Carcinoma Screening in Patients with Cirrhosis. (2021) (27)
Improved Post-Transplant Survival in the United States for Patients with Cholangiocarcinoma After 2000 (2011) (26)
Elevated Serum IL-8 Is Associated with the Presence of Hepatocellular Carcinoma and Independently Predicts Survival (2012) (26)
Immune thrombocytopenic purpura following liver transplantation: A case series and review of the literature (2006) (26)
Staging systems for hepatocellular carcinoma: should we all use the BCLC system? (2006) (26)
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: A subanalysis from the SHARP trial (2008) (25)
Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma (2020) (25)
Benefits and Harms of Hepatocellular Carcinoma Surveillance in a Prospective Cohort of Patients with Cirrhosis. (2020) (24)
Treatment of primary biliary cirrhosis with tetrathiomolybdate: results of a double-blind trial. (2010) (23)
Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study (2019) (23)
GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis (2021) (23)
Altered Functionality of Anti-Bacterial Antibodies in Patients with Chronic Hepatitis C Virus Infection (2013) (23)
Who Decides? Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma (2006) (22)
Validation of a novel model for the early detection of hepatocellular carcinoma (2019) (22)
Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. (2013) (22)
Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice. (2004) (21)
Risk Factors for Cirrhosis in Contemporary Hepatology Practices-Findings from Texas Hepatocellular Carcinoma Consortium Cohort. (2020) (20)
A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. (2021) (19)
Diagnostic and Therapeutic Delays in Patients With Hepatocellular Carcinoma. (2021) (19)
Modern diagnosis of hepatocellular carcinoma: Utilization of liver biopsy and genomic markers. (2009) (18)
A comparison of statistical methods for the detection of hepatocellular carcinoma based on serum biomarkers and clinical variables (2013) (18)
Simultaneous Liver-Kidney Transplantation in Liver Transplant Candidates With Renal Dysfunction: Importance of Creatinine Levels, Dialysis, and Organ Quality in Survival (2016) (16)
Impact of periodontal therapy on systemic markers of inflammation in patients with metabolic syndrome: A randomized clinical trial (2020) (16)
Hepatocellular carcinoma (2005) (16)
Advances in critical care hepatology. (2003) (16)
The role of serum biomarkers in hepatocellular carcinoma surveillance. (2011) (15)
Chronic pancreatitis resulting from primary hydatid disease of the pancreas: a case report and review of the literature. (1999) (15)
Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease (2022) (15)
Risk factors for HCC in contemporary cohorts of patients with cirrhosis (2022) (14)
Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients with Hepatocellular Carcinoma. (2020) (14)
Lack of Benefit and Potential Harm of Induction Therapy in Simultaneous Liver‐Kidney Transplants (2019) (14)
Racial and Ethnic Disparities in Survival Among Patients with Hepatocellular Carcinoma in the United States: A Systematic Review and Meta-Analysis. (2020) (13)
Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute's Early Detection Research Network. (2019) (13)
Alpha-fetoprotein in early hepatocellular carcinoma. (2010) (13)
Prevention of recurrent variceal bleeding: as easy as A.P.C.? (2002) (12)
994 EFFICACY AND SAFETY OF SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA AND PRIOR ANTI-TUMOR THERAPY: A SUBANALYSIS FROM THE SHARP TRIAL (2008) (12)
Biomarkers in cholangiocarcinoma (2014) (11)
Su2057 Machine Learning Algorithms Outperform Conventional Regression Models in Identifying Risk Factors for Hepatocellular Carcinoma in Patients With Cirrhosis (2012) (11)
Donor Factors Similarly Impact Survival Outcome After Liver Transplantation in Hepatocellular Carcinoma and Non-hepatocellular Carcinoma Patients (2013) (11)
Diagnostic accuracy of MRI with extracellular vs. hepatobiliary contrast material for detection of residual hepatocellular carcinoma after locoregional treatment (2018) (10)
Liver transplantation for hepatocellular carcinoma: who benefits and who is harmed? (2008) (10)
Doylestown Plus and GALAD Demonstrate High Sensitivity for HCC Detection in Patients with Cirrhosis. (2021) (9)
Early Survivorship After Liver Transplantation: A Qualitative Study Identifying Challenges in Recovery From the Patient and Caregiver Perspective (2021) (9)
6500 ORAL Second Interim Results of the GIDEON (Global Investigation of Therapeutic DEcisions in HCC and of Its Treatment With SorafeNib) Study – Barcelona-Clinic Liver Cancer (BCLC) Stage Subgroup Analysis (2011) (9)
Improved biomarker performance for the detection of hepatocellular carcinoma by inclusion of clinical parameters (2012) (9)
First interim results of the global investigation of therapeutic decisions in hepatocellular carcinoma (HCC) and of its treatment with sorafenib (GIDEON) study: Use of sorafenib (Sor) by oncologists and nononcologists in the management of HCC. (2011) (8)
Obesity and Liver Disease: The New Era of Liver Transplantation (2019) (8)
Role of liver transplantation in the treatment of cholangiocarcinoma (2009) (8)
What Survivorship Means to Liver Transplant Recipients: Qualitative Groundwork for a Survivorship Conceptual Model (2021) (8)
Surveillance for Hepatocellular Carcinoma. (2020) (7)
CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT -Fetoprotein, Des- Carboxyprothrombin, and Lectin-Bound -Fetoprotein in Early Hepatocellular Carcinoma (2009) (7)
Hepatocellular carcinoma (2003) (7)
Gastrointestinal tumors, non-colorectal (2012) (6)
Molecular signature predictive of long-term liver fibrosis progression to inform anti-fibrotic drug development (2021) (6)
Cachexia is Prevalent in Patients with Hepatocellular Carcinoma and Associated with Worse Prognosis. (2021) (5)
81 GIDEON (GLOBAL INVESTIGATION OF THERAPEUTIC DECISIONS IN HCC AND OF ITS TREATMENT WITH SORAFENIB) STUDY FIRST INTERIM RESULTS: SORAFENIB DOSING ACROSS REGIONS AND DISEASE SUBGROUPS (2011) (5)
“Raising HOPE”: Improved Outcomes for HIV/HCV-coinfected Liver Transplant Recipients in the Direct-acting Antiviral Era (2021) (5)
High Neutrophil–Lymphocyte Ratio and Delta Neutrophil–Lymphocyte Ratio Are Associated with Increased Mortality in Patients with Hepatocellular Cancer (2021) (5)
Outcomes of Simultaneous Liver Kidney Transplantation in Patients With Hepatocellular Carcinoma (2017) (5)
Can dietary fish intake prevent liver cancer? (2012) (5)
P0372 : Gideon: A retrospective analysis of prognostic factors for survival (2015) (5)
1261 GP73, a resident golgi membrane protein, appears in sera of patients with viral liver disease and hepatocellular cancer (2003) (4)
Correction: A comparison of statistical methods for the detection of hepatocellular carcinoma based on serum biomarkers and clinical variables (2013) (4)
Direct‐acting antivirals and recurrence of hepatocellular carcinoma (2017) (3)
A Novel Biomarker Panel for the Early Detection and Risk Assessment of Hepatocellular Carcinoma in Patients with Cirrhosis (2021) (3)
Editorial: ultrasound surveillance of hepatocellular carcinoma in the 21st century – authors' reply (2017) (3)
632 Discrepancy Between Virological Breakthrough and Confirmed Genotypic Resistance in Chronic Hepatitis B Patients Receiving Nucleos(T)Ide Analogue Therapy in Clinical Practice (2010) (3)
HCC Surveillance: Striving for a Better Balance of Benefits and Harms. (2017) (3)
Interferon Therapy and Prevention of Hepatocellular Carcinoma in Hepatitis C (2012) (3)
Expansion of Criteria for Liver Transplantation in Hepatocellular Carcinoma: Better Patient Selection or a Slippery Slope? (2017) (3)
Tu1004 Failure Rates in a Surveillance Program for Hepatocellular Carcinoma Among Patients in the HALT-C Trial (2012) (3)
Second interim analysis of GIDEON (Global Investigation of Therapeutic Decisions in Unresectable HCC and of Its Treatment with Sorafenib): Sorafenib treatment and safety in U.S. patients with Child-Pugh B status. (2012) (3)
Isoform Specific Antisera for the Na+/K+-ATPase β1 and β2 Subunits: Localization in Fetal Rat Tissues (1994) (3)
Worldwide trends in locoregional therapy for hepatocellular carcinoma (HCC): Second interim analysis of the Global Investigation of Therapeutic Decisions in HCC and of Its Treatment with Sorafenib (GIDEON) study. (2012) (2)
Second interim analysis of GIDEON (Global Investigation of Therapeutic Decisions in Unresectable HCC and of Its Treatment with Sorafenib): U.S. versus global perspective on patient and disease characteristics, treatment history, and sorafenib use. (2012) (2)
Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. (2013) (2)
Epidemiology of hepatocellular carcinoma and cholangiocarcinoma (2009) (2)
Applications of immunoassay to therapeutic drug monitoring (1984) (2)
A blood-based prognostic liver secretome signature predicts long-term risk of hepatic decompensation in cirrhosis. (2021) (2)
Human colonic epithelial cells express galanin-1 receptors, which when activated cause Cl- secretion. (1999) (2)
Hepatocellular carcinoma. (2002) (2)
Final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafeNib) in > 3000 sorafenib-treated patients: Prognostic value of baseline characteristics and staging systems (2013) (2)
Website Review: Patient-Oriented Websites (MedicineNet, WebMD, Wikipedia, eMedicine, Department of Veterans Affairs, and UpToDate) on Hepatocellular Carcinoma (2014) (1)
A cost comparison of the diagnostic modalities used in the detection of urothelial carcinoma in patients undergoing evaluation for hematuria (2006) (1)
Hepatocellular carcinoma. (2006) (1)
Validation of the Galad Score for Hepatocellular Carcinoma Diagnosis in a Us Cohort (2016) (1)
Erratum: First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study (International Journal of Clinical Practice (2012) 66 (675-683)) (2012) (1)
Galanin causes Cl− secretion in T84 cells: Identification of a novel mechanism for infectious diarrhea* (1998) (1)
A novel non-invasive index is useful in excluding both significant fibrosis and cirrhosis in chronic hepatitis C (CHC) patients (2003) (1)
SERUM-PROTEIN ALTERATIONS IN PANCREATIC CANCER PATIENTS AND THEIR USE FOR DISEASE CLASSIFICATION (2005) (1)
16 RISK OF PROGRESSION TO HEPATOCELLULAR CARCINOMA IN PATIENTS WITH INDETERMINATE (LI-RADS 3) OBSERVATIONS (2021) (1)
Tu1502 - Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis (2018) (1)
Chapter 57 – Hepatocellular Carcinoma (2012) (1)
711 Patient Involvement is Associated With Higher HCC Surveillance Rates in Patients With Cirrhosis (2010) (1)
Update in Nonpulmonary Critical Care Advances in Critical Care Hepatology (2003) (1)
Association of the establishment of multidisciplinary (MDC) hepatocellular carcinoma (HCC) clinic with clinical outcome. (2013) (1)
Second interim analysis of the Global Investigation of Therapeutic Decisions in Unresectable HCC and of Its Treatment with Sorafenib (GIDEON): Sorafenib dosing and safety in U.S. patients. (2012) (1)
Hepatocellular Carcinoma Surveillance Is Associated With Potential Harms: 2134 (2015) (1)
A comparison of statistical methods for the detection of hepatocellular carcinoma based on serum biomarkers and clinical variables (2013) (0)
Mo1040 The Impact of Hispanic Ethnicity on Clinical Presentation, Treatment and Outcomes Among Patients With Hepatocellular Carcinoma (2014) (0)
Mo1048 Patient-Reported Barriers to Hepatocellular Carcinoma Surveillance Among Patients With Cirrhosis (2015) (0)
B and increases galanin-1 receptor expression κ NF-sulfate sodium-induced murine colitis activates (2016) (0)
Mo1054 Poor Quality of Life in Patients With Hepatocellular Carcinoma Associated With Worse Prognosis (2014) (0)
Validation of a novel model for the early detection of hepatocellular carcinoma (2019) (0)
Abstract No. 241: Worldwide trends in locoregional therapy for hepatocellular carcinoma (HCC): First interim analysis of the global investigation of therapeutic decisions in HCC and of its treatment with sorafenib (GIDEON) study (2011) (0)
Clinical Outcomes of Patients with LI-RADS 3 or LI-RADS 4 Observations in Patients with Cirrhosis: A Systematic Review. (2022) (0)
Clinical outcomes of patients with Liver Imaging Reporting and Data System 3 or Liver Imaging Reporting and Data System 4 observations in patients with cirrhosis: A systematic review (2022) (0)
Relationship Between Diabetes Mellitus and Adenocarcinoma of the Esophagus and Gastric Cardia: 1 (2005) (0)
ErratumTo: A comparison of statistical methods for the detection of hepatocellular carcinoma based on serum biomarkers and clinical variables (2013) (0)
Fr384 DOYLESTOWN PLUS ALGORITHM AS A NOVEL BIOMARKER TO DETECT HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CIRRHOSIS (2021) (0)
Screening for hepatocellular carcinoma in viral liver disease: any new biomarkers on the horizon? (2020) (0)
Electrophysiological characterization of human sigmoid colon epithelium resected using a novel endoscopic technique (1998) (0)
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma : Subanalyses of a phase III trial q , qq (2012) (0)
Reply: Wang et al, "Should growth pattern of hepatocellular carcinoma be constant and homogenous?" (2020) (0)
Mo1337 Clinical Predictors of Malignant Biliary Strictures (2012) (0)
Current therapeutic armamentarium for HCC (2008) (0)
Reply to Giannini and Trevisani (2013) (0)
Functional Disability and Informal Caregiving Among Older Patients With Decompensated Cirrhosis: An Analysis of the Health and Retirement Study (2011) (0)
Knowledge of Hepatocellular Carcinoma (HCC) Screening Guidelines and Current Practices: Results of a National Survey: 900 (2007) (0)
Gideon (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma [HCC] and of Its Treatment with Sorafenib [SOR]) 2nd Interim Analysis (IA): Subgroup Analysis by Disease Etiology (2012) (0)
Computed Tomographic Colonography Accuracy: Nonpolypoid Neoplasms (2010) (0)
Surveillance and screening for hepatocellular carcinoma (2009) (0)
Screening and Biomarkers for Hepatocellular Carcinoma (2009) (0)
M1902 Detection of Entecavir-Resistant (ETV-R) Mutations in Nucleoside-NaïVe and in Lamivudine-Refractory (Lvd-R) HBV Patients and Implications On Response to ETV Treatment (2008) (0)
Fr383 ULTRASOUND QUALITY FOR HEPATOCELLULAR CARCINOMA IN PATIENTS WITH CIRRHOSIS (2021) (0)
253 Smoking, obesity and alcohol are important risk factors in American patients with hepatocellular carcinoma: a case control study (2003) (0)
Tu1047 Infiltrative Hepatocellular Carcinoma (HCC): Natural History and Variables Predictive of Survival (2013) (0)
Clinical roundtable monograph: A multidisciplinary approach to the management of hepatocellular carcinoma (2010) (0)
Mo1026 Diagnostic Delays During Hepatocellular Carcinoma Surveillance Are Common (2013) (0)
Mo1479 Serum Alpha Fetoprotein in Hepatocellular Carcinoma: Effect of Etiology, Race, and Severity of Liver Inflammation (2016) (0)
530: RISK STRATIFICATION MODEL FOR HEPATOCELLULAR CANCER IN PATIENTS WITH CIRRHOSIS (2022) (0)
Screening for Hepatocellular Carcinoma in Viral Liver Disease: Is Ultrasound Enough? (2010) (0)
CEBP FOCUS Biomarkers for the Early Detection of Hepatocellular Carcinoma (2020) (0)
Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score (2023) (0)
Hepatocellular carcinoma. (2001) (0)
AGI May 41/5 (2000) (0)
Medical options for late-stage tumors and ongoing research for future HCC treatment (2009) (0)
356 RACIAL AND ETHNIC DISPARITIES IN SURVIVAL AMONG PATIENTS WITH HEPATOCELLULAR CARCINOMA IN THE UNITED STATES: A SYSTEMATIC REVIEW AND META-ANALYSIS (2021) (0)
Association of adiponectin in patatin-like phospholipase domain-containing 3 (PNPLA3) associated hepatic steatosis. (2014) (0)
T1925 The Efficacy of Ultrasound As a Surveillance Tool for the Early Detection of Hepatocellular Carcinoma (2008) (0)
Present and future of liver transplantation (2019) (0)
REPLY: (2021) (0)
109 GIDEON (GLOBAL INVESTIGATION OF THERAPEUTIC DECISIONS IN HEPATOCELLULAR CARCINOMA AND OF ITS TREATMENT WITH SORAFENIB) SECOND INTERIM ANALYSIS: CLINICAL FINDINGS IN CHILD-PUGH B SCORE SUBGROUPS (2012) (0)
Hepatobiliary Cancers Clinical Practice Guidelines in OncologyTM (2009) (0)
C57BL/6J mice: characterization of a new animal model Azoxymethane-induced fulminant hepatic failure in (2012) (0)
Azoxymethane-induced fulminant hepatic failure (FHF) in mice: Characterization of a new animal model† (1998) (0)
354 GALAD DEMONSTRATES HIGH SENSITIVITY FOR EARLY-STAGE DETECTION OF HEPATOCELLULAR CARCINOMA IN A COHORT OF PATIENTS WITH CIRRHOSIS (2021) (0)
1045 - Mailed Outreach Invitations and Patient Navigation Significantly Improve Hepatocellular Carcinoma Surveillance Rates in Patients with Cirrhosis: A Randomized Controlled Trial (2018) (0)
Abstract No. 196: Worldwide trends in locoregional therapy (LRT) for hepatocellular carcinoma (HCC): 2nd interim analysis (IA; 1500 patients [pts]) of the GIDEON (global investigation of therapeutic decisions in HCC and of its treatment with sorafenib) study (2012) (0)
Primary Carcinomas of the Liver: Staging of hepatocellular carcinoma (2009) (0)
ACR Appropriateness Criteria® Management of Liver Cancer: 2022 Update. (2022) (0)
Mo1044 Patient-Level Knowledge About Hepatocellular Carcinoma Surveillance Among Patients With Cirrhosis (2015) (0)
Sa337 PRECEDING ULTRASOUND VISUALIZATION PREDICTS QUALITY OF FUTURE SURVEILLANCE IN PATIENTS WITH CIRRHOSIS (2021) (0)
S1893 Predictors of Knowledge Regarding Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis (2010) (0)
Sa333 CACHEXIA IS PREVALENT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AND ASSOCIATED WITH WORSE SURVIVAL (2021) (0)
720 Extrahepatic Metastasis Plus Vascular Invasion in Patients With Hepatocellular Carcinoma (HCC) Portends a Worse Prognosis Than Extrahepatic Metastasis or Vascular Invasion Alone (2013) (0)
Response to Zanini et al. (2015) (0)
Tu1491 - Early Tumor Detection and Curative Treatment Receipt Mediate Racial and Ethnic Disparities in Hepatocellular Carcinoma Prognosis (2018) (0)
Reply: (2005) (0)
949: PROGNOSTIC LIVER SECRETOME SIGNATURE AND ALPHA-FETOPROTEIN (PLSEC-AFP) PREDICTS LONG-TERM HEPATOCELLULAR CARCINOMA RISK IN PATIENTS WITH CIRRHOSIS: A NATIONWIDE PHASE 3 BIOMARKER STUDY IN THE U.S. (2022) (0)
Hepatocellular carcinoma (2002) (0)
Second interim analysis of the Global Investigation of Therapeutic Decisions in Unresectable HCC (uHCC) and of Its Treatment with Sorafenib (GIDEON): Differences in AE reporting across physician specialties. (2012) (0)
Clinical Guideline : The Diagnosis and Management of Focal Liver Lesions (2014) (0)
794 Institution of a Multidisciplinary Liver Tumor Clinic Reduces Therapeutic Delays for Patients With Hepatocellular Carcinoma (2013) (0)
SELDI-TOF-MS profiling of serum for detection of hepatocellular carcinoma progression in hepatitis B and hepatitis C infected patients* (2003) (0)
1239 MELD score is a better predictor of mortality than tumor characteristics in inoperable hepatocellular carcinoma in the United States (2003) (0)
Applications and Limitations of Surgical and Regional Therapeutic Techniques (2010) (0)
1000 Older Adults With Hepatocellular Carcinoma Are More Likely Than Younger Adults to Receive Curative Treatment but Have Worse Overall Survival (2019) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With J. Avila Marrero?

J. Avila Marrero is affiliated with the following schools:

University of Michigan
Fudan University
University of Texas Southwestern Medical Center
University of Illinois Chicago